Navigation Links
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
Date:11/19/2013

p>Forward-looking statements

This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of DAIICHI SANKYO, Co. Ltd. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. DAIICHI SANKYO, Co. Ltd. assume no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.

References

1.        Ruff, C et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-41.

2.        Giugliano, RP et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013.

3.        Ball, J et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol. 2013;167:1807–24.

4.    &#
'/>"/>

SOURCE Daiichi Sankyo
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
2. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
3. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
4. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
5. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
8. Sosei Group Corporation: QVA149 Filed by Licensing Partner as a Once-Daily Maintenance Treatment for COPD in Japan
9. Sosei Group Corporation: QVA149 Filed as a Once-Daily Maintenance Treatment for COPD in Europe
10. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
11. Coherus Announces CHS-0214 (Proposed Etanercept Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Calif., Dec. 18, 2014 Capnia, Inc. ... development of medical diagnostics based on its proprietary ... flow, today announced financial results for the third ... "Following the completion of our initial ... to maximize the recently initiated CoSense® commercial launch," ...
(Date:12/19/2014)... WASHINGTON , Dec. 18, 2014 Since ... Road, the site now known as the leading online ... has seen explosive growth in its offering of drugs ... Citizens Alliance show the takedowns did succeed in lowering ... our last review of the markets in August. But ...
(Date:12/19/2014)... has witnessed robust development with the growth pace keeping at ... In 2012, the size of China ... worldwide soaring to 16.3%. It is projected that ... rate by around 20% in the upcoming years and that ... An integrated membrane industrial system has taken shape ...
Breaking Medicine Technology:Capnia Reports Third Quarter 2014 Financial Results 2Capnia Reports Third Quarter 2014 Financial Results 3Capnia Reports Third Quarter 2014 Financial Results 4Capnia Reports Third Quarter 2014 Financial Results 5Capnia Reports Third Quarter 2014 Financial Results 6Capnia Reports Third Quarter 2014 Financial Results 7Capnia Reports Third Quarter 2014 Financial Results 8Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 2Separation Membranes Market (Company, Country & Application) Research Reports for Global and Chinese Regions 3
... Ind., Oct. 18, 2011 ... biopharmaceutical cGMP storage, supply chain management, prescription drug ... they have signed a five-year contract with the ... Supply Schedule, Logistics Worldwide (LogWorld). Inclusion on this ...
... YORK, Oct. 18, 2011 Reportlinker.com announces ... available in its catalogue: ... to 2015 http://www.reportlinker.com/p0535967/The-Global-Pharmaceutical-Fine-Chemicals-Market-Outlook-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Chemical_and_Material ... This report provides a comprehensive overview ...
Cached Medicine Technology:Sentry BioPharma Services Earns a GSA Federal Supply Schedule Contract #GS-10F-0432X 2Sentry BioPharma Services Earns a GSA Federal Supply Schedule Contract #GS-10F-0432X 3The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 2The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 3The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 4The Global Pharmaceutical Fine Chemicals Market Outlook to 2015 5
(Date:12/21/2014)... Thompson HealthDay Reporter FRIDAY, ... e-cigarettes less addictive than traditional cigarettes, new research finds. ... did regular cigarettes, thousands of ex-smokers said they have fewer ... over their need to smoke, researchers reported. ... less for e-cig use than for tobacco use," said lead ...
(Date:12/21/2014)... NY (PRWEB) December 21, 2014 The ... 1,400 in a consolidated litigation underway in New Jersey, ... a total of 1,375 claims involving the birth control ... Court. These lawsuits were filed by women who allege ... have led to uterine perforations and other complications they ...
(Date:12/21/2014)... San Francisco, California (PRWEB) December 21, 2014 ... announces his search for Vintage 1967 Jm Morrison and the ... D.C. concert posters. This would also be the only ... live. The concert was on Nov. 25, 1967. According ... in Washington D.C. They did play the Alexandria Roller ...
(Date:12/21/2014)... Over the past 39 years, NES Health has ... departments across the nation, from quality of medical care ... an innovative suite of tools, systems, and programs that ... patient experience. , NES Health, a leading national ... for hospitals, announced the development and launch of its ...
(Date:12/21/2014)... Theme and plugin developers ... plugin for Final Cut Pro X entitled ProMotion. , ... more with absolute ease.” Said Christiana Austin, CEO of ... needed to easily animate their media inside FCPX.” , ... users to animate pictures, videos, logos, and more with ...
Breaking Medicine News(10 mins):Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2
... Best Care Senior,Services has expanded into the Littleton/Denver, ... Service, and Personal,Response Company, is proud to announce ... Care Senior Services for outstanding care. For over ... of our work -- a,sincere concern for the ...
... Blood and Plasma Donor Centers, LENEXA, Kan., ... MEDW ), a provider of ClosedLoop(TM) clinical,systems for ... has,completed the acquisition of substantially all of the ... provider of software products and,services that enable blood ...
... Industry Sales Increase as Consumers Put Their Trust in Natural, Effective ... ... Oct. 31 There has been a profound shift in,the thinking ... become increasingly proactive in seeking more natural means to fight,sickness. As ...
... machinery in a cell to serve their own needs. According ... to gain access to that machinery. , A common target ... or pRb, which serves to block cell division when potentially ... of the retina, this tumor suppressor protein has since been ...
... if drug would have same benefit for Caucasians , , ... cancer with an experimental chemotherapy drug after surgery improved ... , The results of the trial won,t mean much ... S-1, is classified as "investigational" in the United States. ...
... The Medicare bidding,program for durable medical equipment will ... unless Congress modifies,the program. This is the key ... today by the American Association for Homecare.,The Association ... care, choice of provider, and access to the ...
Cached Medicine News:Health News:Announcing Always Best Care Senior Services Expansion Into the Littleton/Denver, Colorado Area 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 3Health News:Hyland's Inc. Reports More Consumers Turn to Homeopathic Medicines to Fight Illness at Home 2Health News:How one virus uses mimicry to replicate successfully 2Health News:Chemo Drug Improves Stomach Cancer Survival for Japanese Patients 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 3
... Anchor is available in 3.5 mm, 5 mm ... minor diameter and a cancellous screw thread design ... laser mark on the distal part of the ... eyelets. When the anchor is inserted, the vertical ...
... - As easy to use as its ... demanding medical justification of therapeutic procedures. For ... tract symptoms (LUTS), that requires urodynamics. ... becoming routine in the office environment, with ...
... The FASTak II Suture Anchor is a ... that is inserted directly into bone without predrilling ... the Tear Drop Handle, Keyless Chuck or the ... and SLAP repairs as well as other small ...
... offer the best bioabsorbable solution for soft ... thread design and small core diameter provide ... braided suture loop is molded into the ... eyelet that virtually eliminates abrasion to attached ...
Medicine Products: